Tuesday, April 8, 2014
Sunesis announces results at AACR - Wedbush reiterates $10 price target
As expected, Sunesis (SNSS) reported positive preliminary results of it's lead compound, Vosaroxin, in a phase 1b/2 study in AML and MDS. The drug, combined with decitabine, had an overall response rate of 67% in the 24 patients treated. Webush commented on the results and reiterated it's $10 price target on Sunesis.